menu
    • menu
    [{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Regulated Induced Proximity Targeting Chimeras Therapeutic","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Halda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Halda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Halda Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"HLD-0915","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Halda Therapeutics","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Halda Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"14","companyTruncated":"Halda Therapeutics \/ Deep Track Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Halda Therapeutics

    Menu

    Halda Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Halda Therapeutics

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed

                            Halda Therapeutics

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLD-0915

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Deep Track Capital

                            Deal Size : $126.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies

                            Details : The proceeds from the financing will be used to advance two RIPTAC candidates into clinical trials, including HLD-0915, for patients with prostate cancer and breast cancer.

                            Brand Name : HLD-0915

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : HLD-0915

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Deep Track Capital

                            Deal Size : $126.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Halda Therapeutics

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed

                            Halda Therapeutics

                            U.S.A arrow
                            SupplySide West 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Regulated Induced Proximity Targeting Chimeras Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Halda Therapeutics Unveils Its First Pipeline Data For RIPTAC™ therapeutics, A New Drug Modality, at ASCO GU...

                            Details : RIPTAC is a bifunctional small molecules that selectively target tumors by holding a tumor-specific protein and a protein with essential function together in a trimeric complex which involves the formation of neo protein-protein-interactions.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 14, 2023

                            Lead Product(s) : Regulated Induced Proximity Targeting Chimeras Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth